Back to top
more

Cytokinetics (CYTK)

(Delayed Data from NSDQ)

$65.34 USD

65.34
734,584

+0.54 (0.83%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $65.32 -0.02 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cytokinetics (CYTK) Surges 40.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Company News for Jul 20, 2021

by Zacks Equity Research

Companies in The News Are: CALM,FIVN,ZM,NGG,CYTK

Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cytokinetics (CYTK) delivered earnings and revenue surprises of -11.86% and -16.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Cytokinetics (CYTK) is Overbought: Is A Drop Coming?

by Zacks Equity Research

Cytokinetics (CYTK) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Amgen (AMGN) Ends Deal With Cytokinetics for Heart Candidate

by Zacks Equity Research

Amgen (AMGN) will terminate the collaboration with Cytokinetics and transition development and commercialization rights for omecamtiv mecarbil and AMG 594 to the latter.

    Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Cytokinetics (CYTK) delivered earnings and revenue surprises of 91.53% and 997.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

    Analysts Estimate Cytokinetics (CYTK) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Earnings Preview: Cytokinetics (CYTK) Q3 Earnings Expected to Decline

    by Zacks Equity Research

    Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Amgen Down on Unsatisfactory Heart Failure Drug Study Results

    by Zacks Equity Research

    Amgen (AMGN) with partners post top-line data from the phase III GALACTIC-HF study on omecamtiv mecarbil, which is being evaluated for heart failure with reduced ejection fraction. Stock falls.

    Cytokinetics (CYTK) in Focus: Stock Moves 5.7% Higher

    by Zacks Equity Research

    Cytokinetics (CYTK) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

    Are Options Traders Betting on a Big Move in Cytokinetics (CYTK) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to Cytokinetics (CYTK) stock based on the movements in the options market lately.

    Earnings Preview: Cytokinetics (CYTK) Q2 Earnings Expected to Decline

    by Zacks Equity Research

    Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    by Zacks Equity Research

    Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Cytokinetics (CYTK) delivered earnings and revenue surprises of -23.81% and -27.51%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

    Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    by Zacks Equity Research

    Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Sweta Killa headshot

    Small-Cap Healthcare ETF Outperforming in 2020: 5 Top Stocks

    by Sweta Killa

    The small-cap healthcare companies are benefiting from the 2020 presidential election campaign, which has put pressure on the large cap cousins on how to overhaul the industry.

    Implied Volatility Surging for Cytokinetics (CYTK) Stock Options

    by Zacks Equity Research

    Investors need to pay close attention to Cytokinetics (CYTK) stock based on the movements in the options market lately.

    Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Cytokinetics (CYTK) delivered earnings and revenue surprises of 10.71% and -22.37%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

    Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Cytokinetics (CYTK) delivered earnings and revenue surprises of -5.66% and 4.88%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

    Analysts Estimate Cytokinetics (CYTK) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Analysts Estimate Cytokinetics (CYTK) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Cytokinetics (CYTK) delivered earnings and revenue surprises of -14.89% and 36.41%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

    Will Cytokinetics (CYTK) Report Negative Earnings Next Week? What You Should Know

    by Zacks Equity Research

    Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Will Cytokinetics (CYTK) Report Negative Q1 Earnings? What You Should Know

    by Zacks Equity Research

    Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.